Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Neil Mehta, M.D.
Neil Mehta, M.D.

Neil Mehta, M.D.

Assistant Professor of Medicine
General Hepatology and Liver Transplantation
Department of Medicine

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357     
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Open Popup

Johns Hopkins University, BA, Neuroscience, 1998-2002

University of California, San Francisco School of Medicine, MD, 2002-2006

  • Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
  • Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009
  • University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
  • University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013
  • American Board of Internal Medicine
  • American Board of Internal Medicine - Gastroenterology
  • American Board of Internal Medicine - Transplant Hepatology
  • UCSF Liver Center
  • Cardiopulmonary complications of chronic liver disease
  • Hepatocellular carcinoma (HCC)
  • Liver injury and repair (Liver transplantation)
  • Liver transplantation outcomes including expanded criteria liver transplants

Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.

After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

MOST RECENT PUBLICATIONS FROM A TOTAL OF 112
Data provided by UCSF Profiles, powered by CTSI
  1. Hepatic Toxicity After Selective Chemoembolization Is Associated With Decreased Survival Among Patients With Hepatocellular Carcinoma. AJR Am J Roentgenol. 2021 Mar 11; 1-8. View in PubMed
  2. Harding-Theobald E, Yao FY, Mehta N. Neutrophil-to-Lymphocyte ratio predicts high risk explant features and waitlist survival but is not independently associated with recurrence or survival following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2021 Feb 11. View in PubMed
  3. Kotwani P, Chan W, Yao F, Mehta N. DCP and AFP-L3 are Complementary to AFP in Predicting High-risk Explant Features: Results of a Prospective Study. Clin Gastroenterol Hepatol. 2021 Jan 29. View in PubMed
  4. Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-Based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation. 2020 Dec 14. View in PubMed
  5. Lee BP, Im GY, Rice JP, Lazar A, Weinberg E, Han H, Maddur H, Ghobrial RM, Therapondos G, Hsu C, Fix OK, Eswaran S, Shetty K, Chhatwal J, Dalgic OO, Jakhete N, Mobley C, Victor DW, Mehta N, Dinges L, Rinella M, Schiano TD, Lucey MR, Terrault N. Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2020 Dec 03. View in PubMed
  6. View All Publications

 

Site Directory
    X